What is the fair value of Rallybio Corp (NASDAQ-RLYB) stock?

The current fair value estimate for Rallybio Corp (NASDAQ-RLYB) is $14.74. This implies an estimated downside of 12.9% versus the current market price.

Is Rallybio Corp (NASDAQ-RLYB) undervalued or overvalued?

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 12.9% versus the current market price.

What is the analyst price target for NASDAQ-RLYB stock?

The available analyst price target for Rallybio Corp (NASDAQ-RLYB) is $8. The analyst target implies estimated downside of 52.7%.

How is the financial health of Rallybio Corp?

The current financial health read for Rallybio Corp (NASDAQ-RLYB) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is Rallybio Corp's next earnings date?

The next earnings date currently listed for Rallybio Corp (NASDAQ-RLYB) is November 6, 2026.

Does Rallybio Corp (NASDAQ-RLYB) pay dividends?

The latest available data indicates no current dividend yield for Rallybio Corp (NASDAQ-RLYB).

What is the P/E ratio for Rallybio Corp (NASDAQ-RLYB)?

The current P/E ratio listed for Rallybio Corp (NASDAQ-RLYB) is 2.0x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

What is the market capitalization of Rallybio Corp?

The current market capitalization listed for Rallybio Corp is 89.854 M.

What is the enterprise value of Rallybio Corp?

The current enterprise value listed for Rallybio Corp is -2.942 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for Rallybio Corp?

The ticker symbol for Rallybio Corp is NASDAQ-RLYB, and the stock is listed on NASDAQ.

Where is Rallybio Corp (NASDAQ-RLYB) listed?

Rallybio Corp (NASDAQ-RLYB) is listed on NASDAQ.

What is the debt-to-total-capital ratio for Rallybio Corp?

The current debt-to-total-capital ratio listed for Rallybio Corp is 0.0%, which helps investors evaluate the company’s financing structure and leverage profile.

What is the free float for Rallybio Corp?

The free float listed for Rallybio Corp is 33.1%. Free float helps investors understand how much of the share base is available for public trading.

Rallybio Corp (RLYB) Fair Value & Stock Analysis

Rallybio Corp (RLYB)

Rallybio Corp is a clinical-stage biotechnology company focused on developing and commercializing therapies for patients with severe and rare diseases. Its pipeline includes RLYB116, an inhibitor of complement component 5 (C5) that has completed a phase 1 trial for diseases linked to complement dysregulation, and RLYB332, a preclinical antibody being studied for severe anemia with ineffective erythropoiesis and iron overload. The company also maintains a strategic alliance with AbCellera to discover, develop, and commercialize antibody-based therapeutics for rare diseases, along with a collaboration with Johnson & Johnson aimed at therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio was founded in 2018 and is headquartered in New Haven, Connecticut.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Analyst Target Rating	Overall Financial Health	Dividend Yield	Next Earnings Date	P/E Ratio	Price-to-Book Ratio	Price-to-Sales Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Free Cash Flow / Net Income
NASDAQ-RLYB	$14.74	-12.9% Downside	Fair	$8	-52.7% Downside	Expensive	Great	0.0%	November 6, 2026	2.0x	1.0x	139.2x	89.854 M	-2.942 M	0.0%	33.1%	26.7	58.6%